Enliven Therapeutics (NASDAQ:ELVN) Director Sells 158,795 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Mika Derynck sold 158,795 shares of the stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $60.21, for a total value of $9,561,046.95. Following the completion of the sale, the director owned 87,373 shares in the company, valued at approximately $5,260,728.33. This trade represents a 64.51% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Enliven Therapeutics Trading Up 1.0%

ELVN stock traded up $0.57 during midday trading on Thursday, reaching $60.27. 1,679,203 shares of the company were exchanged, compared to its average volume of 962,013. The business has a 50-day moving average price of $48.21 and a two-hundred day moving average price of $39.53. Enliven Therapeutics, Inc. has a one year low of $14.78 and a one year high of $62.32.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.10). Equities analysts anticipate that Enliven Therapeutics, Inc. will post -1.57 EPS for the current year.

Key Headlines Impacting Enliven Therapeutics

Here are the key news stories impacting Enliven Therapeutics this week:

• Positive Sentiment: Encouraging clinical progress: Enliven reported positive Phase 1 data for ELVN-001 in chronic myeloid leukemia, including encouraging efficacy and a favorable safety and tolerability profile. The company also said it reached agreement with the FDA on key components of the drug’s Phase 3 trial design. Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
• Positive Sentiment: Strong financial runway: Enliven ended the quarter with $895 million in cash, cash equivalents and marketable securities, which management expects to fund operations into 2030. This reduces near-term financing and dilution concerns for investors.
• Positive Sentiment: Analyst target increases: Goldman Sachs raised its price target from $67 to $80 and maintained a “buy” rating. Stifel Nicolaus also raised its target, from $80 to $82, while maintaining a “buy” rating. The revisions imply substantial upside from the stock’s recent trading level. Goldman Sachs price target update Stifel Nicolaus price target update
• Neutral Sentiment: Director sale: Director Mika K. Derynck sold 158,795 shares for approximately $9.6 million, reducing direct ownership by 64.5%. The transaction was conducted under a pre-arranged Rule 10b5-1 plan, which may lessen concerns that the sale reflected a negative view of the company, although the transaction could still weigh on sentiment. SEC insider transaction filing
• Negative Sentiment: Quarterly loss exceeded expectations: Enliven reported a second-quarter loss of $0.49 per share, wider than the $0.39 loss analysts expected. The earnings miss contributed to an earlier pullback in the stock and highlights the company’s continuing lack of profitability. Enliven quarterly earnings release

Hedge Funds Weigh In On Enliven Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ELVN. KBC Group NV acquired a new stake in shares of Enliven Therapeutics during the 1st quarter worth $38,000. Mirae Asset Global Investments Co. Ltd. lifted its position in Enliven Therapeutics by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock worth $44,000 after purchasing an additional 594 shares during the period. BNP Paribas Financial Markets lifted its position in Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after purchasing an additional 930 shares during the period. Los Angeles Capital Management LLC acquired a new stake in Enliven Therapeutics during the fourth quarter worth about $83,000. Finally, Quantbot Technologies LP increased its holdings in Enliven Therapeutics by 47.1% in the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after buying an additional 1,434 shares during the period. 95.08% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have issued reports on ELVN shares. JonesTrading raised their price objective on shares of Enliven Therapeutics from $45.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. HC Wainwright lifted their price target on Enliven Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a report on Thursday, July 9th. Guggenheim reduced their price target on Enliven Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a research note on Thursday. Mizuho upped their price objective on Enliven Therapeutics from $45.00 to $62.00 and gave the company an “outperform” rating in a report on Tuesday, June 2nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Friday, July 17th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $72.67.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.